| 000 | 02355nam a22004457a 4500 | ||
|---|---|---|---|
| 008 | 221213s20222022 xxu||||| |||| 00| 0 eng d | ||
| 022 | _a1198-0052 | ||
| 024 | _a10.3390/curroncol29100541 [doi] | ||
| 024 | _acurroncol29100541 [pii] | ||
| 024 | _aPMC9600738 [pmc] | ||
| 040 | _aOvid MEDLINE(R) | ||
| 099 | _a36290818 | ||
| 245 | _aThe Role of Immunotherapy in Pancreatic Cancer. [Review] | ||
| 251 | _aCurrent Oncology. 29(10):6864-6892, 2022 Sep 23. | ||
| 252 | _aCurr. oncol.. 29(10):6864-6892, 2022 Sep 23. | ||
| 253 | _aCurrent oncology (Toronto, Ont.) | ||
| 260 | _c2022 | ||
| 260 | _fFY2023 | ||
| 260 | _p2022 Sep 23 | ||
| 265 | _sepublish | ||
| 266 | _d2022-12-13 | ||
| 501 | _aAvailable online through MWHC library: 2006 - present | ||
| 520 | _aPancreatic adenocarcinoma remains one of the most lethal cancers globally, with a significant need for improved therapeutic options. While the recent breakthroughs of immunotherapy through checkpoint inhibitors have dramatically changed treatment paradigms in other malignancies based on considerable survival benefits, this is not so for pancreatic cancer. Chemotherapies with modest benefits are still the cornerstone of advanced pancreatic cancer treatment. Pancreatic cancers are inherently immune-cold tumors and have been largely refractory to immunotherapies in clinical trials. Understanding and overcoming the current failures of immunotherapy through elucidating resistance mechanisms and developing novel therapeutic approaches are essential to harnessing the potential durable benefits of immune-modulating therapy in pancreatic cancer patients. | ||
| 546 | _aEnglish | ||
| 650 | _a*Adenocarcinoma | ||
| 650 | _a*Pancreatic Neoplasms | ||
| 650 | _aHumans | ||
| 650 | _aImmunologic Factors | ||
| 650 | _aImmunotherapy | ||
| 650 | _aPancreatic Neoplasms/dt [Drug Therapy] | ||
| 650 | _aPancreatic Neoplasms/pa [Pathology] | ||
| 651 | _aMedStar Washington Hospital Center | ||
| 656 | _aInternal Medicine Residency | ||
| 657 | _aJournal Article | ||
| 657 | _aReview | ||
| 700 |
_aDebnath, Dipanjan _bMWHC _cInternal Medicine Residency _dMBBS _eResident PGY 3 |
||
| 790 | _aDebnath D, Hartley ML, Mukherji R, Noel MS | ||
| 856 |
_uhttps://dx.doi.org/10.3390/curroncol29100541 _zhttps://dx.doi.org/10.3390/curroncol29100541 |
||
| 942 |
_cART _dArticle |
||
| 999 |
_c155 _d155 |
||